Loading...

Mediclinic International

LSE:MDC
Snowflake Description

Moderate growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDC
LSE
£2B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The last earnings update was 125 days ago. More info.


Add to Portfolio Compare Print
MDC Share Price and Events
7 Day Returns
3%
LSE:MDC
2.2%
GB Healthcare
32.1%
GB Market
1 Year Returns
-44.9%
LSE:MDC
-29.7%
GB Healthcare
30.9%
GB Market
MDC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mediclinic International (MDC) 3% -0.4% 0.9% -44.9% -64% -
GB Healthcare 2.2% 0.3% -2.1% -29.7% -15% 160.4%
GB Market 32.1% 31.6% 40.2% 30.9% 48.1% 12.2%
1 Year Return vs Industry and Market
  • MDC underperformed the Healthcare industry which returned -29.7% over the past year.
  • MDC underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 30.9% over the past year.
Price Volatility
MDC
Industry
5yr Volatility vs Market
Related Companies

MDC Value

 Is Mediclinic International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mediclinic International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mediclinic International.

LSE:MDC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for LSE:MDC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.74
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.736 (1 + (1- 28%) (86.55%))
1.13
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (1.13 * 5.96%)
7.96%

Discounted Cash Flow Calculation for LSE:MDC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mediclinic International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

LSE:MDC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 7.96%)
2019 14.66 Est @ -48.62% 13.58
2020 9.72 Est @ -33.67% 8.34
2021 7.47 Est @ -23.2% 5.93
2022 6.28 Est @ -15.87% 4.62
2023 5.61 Est @ -10.74% 3.82
2024 5.21 Est @ -7.15% 3.29
2025 4.96 Est @ -4.64% 2.90
2026 4.82 Est @ -2.88% 2.61
2027 4.74 Est @ -1.65% 2.38
2028 4.71 Est @ -0.78% 2.19
Present value of next 10 years cash flows £49.67
LSE:MDC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £4.71 × (1 + 1.23%) ÷ (7.96% – 1.23%)
£70.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £70.72 ÷ (1 + 7.96%)10
£32.87
LSE:MDC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £49.67 + £32.87
£82.55
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £82.55 / 737.11
£0.11
LSE:MDC Discount to Share Price
Calculation Result
Value per share (GBP) From above. £0.11
Current discount Discount to share price of £3.18
= -1 x (£3.18 - £0.11) / £0.11
-2741.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Mediclinic International is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mediclinic International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mediclinic International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
LSE:MDC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in GBP £-0.83
LSE:MDC Share Price ** LSE (2019-03-20) in GBP £3.18
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PE Ratio Median Figure of 11 Publicly-Listed Healthcare Companies 24.44x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 806 Publicly-Listed Companies 16.06x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mediclinic International.

LSE:MDC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:MDC Share Price ÷ EPS (both in GBP)

= 3.18 ÷ -0.83

-3.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mediclinic International is loss making, we can't compare its value to the GB Healthcare industry average.
  • Mediclinic International is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Mediclinic International's expected growth come at a high price?
Raw Data
LSE:MDC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
48.6%per year
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PEG Ratio Median Figure of 8 Publicly-Listed Healthcare Companies 1.57x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 573 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mediclinic International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mediclinic International's assets?
Raw Data
LSE:MDC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in GBP £4.45
LSE:MDC Share Price * LSE (2019-03-20) in GBP £3.18
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PB Ratio Median Figure of 15 Publicly-Listed Healthcare Companies 1.18x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,359 Publicly-Listed Companies 1.53x
LSE:MDC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:MDC Share Price ÷ Book Value per Share (both in GBP)

= 3.18 ÷ 4.45

0.71x

* Primary Listing of Mediclinic International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mediclinic International is good value based on assets compared to the GB Healthcare industry average.
X
Value checks
We assess Mediclinic International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Mediclinic International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MDC Future Performance

 How is Mediclinic International expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mediclinic International expected to grow at an attractive rate?
  • Mediclinic International's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • Mediclinic International's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Mediclinic International's revenue growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
LSE:MDC Future Growth Rates Data Sources
Data Point Source Value (per year)
LSE:MDC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 48.6%
LSE:MDC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 5.3%
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 27.1%
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 9.6%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 6.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
LSE:MDC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
LSE:MDC Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 3,566 509 272 1
2022-03-31 3,556 468 243 3
2021-03-31 3,270 411 234 9
2020-03-31 3,115 407 211 11
2019-03-31 2,967 342 -47 12
LSE:MDC Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-09-30 2,852 277 -610
2018-06-30 2,861 311 -551
2018-03-31 2,870 345 -492
2017-12-31 2,871 348 -212
2017-09-30 2,871 350 69
2017-06-30 2,810 364 149
2017-03-31 2,749 377 229
2016-12-31 2,565 375 210
2016-09-30 2,380 373 191
2016-06-30 2,244 347 184
2016-03-31 2,107 320 177
2015-12-31 2,080 314 211

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mediclinic International's earnings are expected to grow significantly at over 20% yearly.
  • Mediclinic International's revenue is expected to grow by 5.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
LSE:MDC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Mediclinic International Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:MDC Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 0.37 0.37 0.37 1.00
2022-03-31 0.33 0.33 0.33 1.00
2021-03-31 0.33 0.34 0.29 5.00
2020-03-31 0.29 0.32 0.26 8.00
2019-03-31 -0.06 -0.04 -0.07 5.00
LSE:MDC Past Financials Data
Date (Data in GBP Millions) EPS *
2018-09-30 -0.83
2018-06-30 -0.75
2018-03-31 -0.67
2017-12-31 -0.29
2017-09-30 0.09
2017-06-30 0.20
2017-03-31 0.31
2016-12-31 0.29
2016-09-30 0.28
2016-06-30 0.28
2016-03-31 0.30
2015-12-31 0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Mediclinic International is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Mediclinic International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mediclinic International has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MDC Past Performance

  How has Mediclinic International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mediclinic International's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mediclinic International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mediclinic International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mediclinic International's 1-year growth to the GB Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Mediclinic International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mediclinic International Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:MDC Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 2,852.00 -610.00 739.00
2018-06-30 2,861.00 -551.00 741.00
2018-03-31 2,870.00 -492.00 743.00
2017-12-31 2,870.50 -211.50 742.00
2017-09-30 2,871.00 69.00 741.00
2017-06-30 2,810.00 149.00 715.00
2017-03-31 2,749.00 229.00 689.00
2016-12-31 2,564.50 210.00 666.50
2016-09-30 2,380.00 191.00 644.00
2016-06-30 2,243.50 184.00 599.00
2016-03-31 2,107.00 177.00 554.00
2015-12-31 2,079.58 210.67 527.39
2015-09-30 2,182.50 257.26 530.10
2015-06-30 2,041.57 245.34 491.96
2015-03-31 1,977.00 241.00 471.00
2014-12-31 1,900.82 220.71 432.84
2014-09-30 1,809.82 198.95 398.66
2014-06-30 1,751.38 193.42 381.51
2014-03-31 1,738.30 192.95 374.05
2013-12-31 1,652.04 81.79 360.19
2013-09-30 1,652.85 -33.44 365.70
2013-06-30 1,700.59 -54.63 376.97
2013-03-31 1,742.07 -78.78 386.97
2012-12-31 1,729.45 19.11 385.74
2012-09-30 1,730.12 117.87 387.56
2012-06-30 1,759.50 109.09 397.18
2012-03-31 1,793.47 99.60 408.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mediclinic International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mediclinic International has efficiently used its assets last year compared to the GB Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mediclinic International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mediclinic International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mediclinic International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MDC Health

 How is Mediclinic International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mediclinic International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mediclinic International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mediclinic International's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mediclinic International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mediclinic International Company Filings, last reported 5 months ago.

LSE:MDC Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 3,364.00 2,030.00 243.00
2018-06-30 3,364.00 2,030.00 243.00
2018-03-31 3,373.00 1,939.00 262.00
2017-12-31 3,373.00 1,939.00 262.00
2017-09-30 3,922.00 1,955.00 263.00
2017-06-30 3,922.00 1,955.00 263.00
2017-03-31 4,164.00 2,039.00 377.00
2016-12-31 4,164.00 2,039.00 377.00
2016-09-30 3,948.00 1,994.00 300.00
2016-06-30 3,948.00 1,994.00 300.00
2016-03-31 3,570.00 1,860.00 305.00
2015-12-31 3,570.00 1,860.00 305.00
2015-09-30 2,342.24 1,523.88 274.08
2015-06-30 2,564.58 1,668.54 300.09
2015-03-31 1,840.00 1,645.00 265.00
2014-12-31 1,842.24 1,646.69 265.49
2014-09-30 1,599.37 1,582.90 258.86
2014-06-30 1,613.33 1,596.72 261.13
2014-03-31 1,447.36 1,733.34 200.71
2013-12-31 1,461.90 1,750.75 202.72
2013-09-30 1,353.78 1,762.44 161.83
2013-06-30 1,459.52 1,900.11 174.47
2013-03-31 1,283.38 1,890.07 192.84
2012-12-31 1,318.19 1,916.17 196.19
2012-09-30 913.96 2,160.51 240.15
2012-06-30 954.27 2,255.79 250.74
2012-03-31 930.26 2,327.53 223.27
  • Mediclinic International's level of debt (60.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (130.1% vs 60.3% today).
  • Debt is not well covered by operating cash flow (13.6%, less than 20% of total debt).
  • Mediclinic International is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Mediclinic International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mediclinic International has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MDC Dividends

 What is Mediclinic International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.48%
Current annual income from Mediclinic International dividends. Estimated to be 2.67% next year.
If you bought £2,000 of Mediclinic International shares you are expected to receive £50 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Mediclinic International's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.01%).
  • Mediclinic International's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.17%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
LSE:MDC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.6%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 704 Stocks 4%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

LSE:MDC Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2023-03-31 0.13 1.00
2022-03-31 0.12 2.00
2021-03-31 0.09 11.00
2020-03-31 0.08 13.00
2019-03-31 0.08 13.00
LSE:MDC Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2018-06-22 0.079 2.053
2018-05-24 0.079 1.377
2017-07-25 0.079 1.252
2016-07-20 0.079 0.963
2016-02-16 0.046 0.546

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Mediclinic International has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Mediclinic International only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Mediclinic International's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.6x coverage).
X
Income/ dividend checks
We assess Mediclinic International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mediclinic International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mediclinic International has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MDC Management

 What is the CEO of Mediclinic International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ronnie van der Merwe
COMPENSATION £4,814,000
TENURE AS CEO 0.8 years
CEO Bio

Dr. Ronnie van der Merwe has been Chief Executive Officer and Executive Director of Mediclinic International plc since June 1, 2018 and serves as its Chief Clinical Officer. Dr. van der Merwe has been a Non-Executive Director at Spire Healthcare Group Plc

CEO Compensation
  • Ronnie's compensation has increased whilst company is loss making.
  • Ronnie's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Mediclinic International management team in years:

1.8
Average Tenure
49.5
Average Age
  • The average tenure for the Mediclinic International management team is less than 2 years, this suggests a new team.
Management Team

Petrus Myburgh

TITLE
Group CFO & Executive Director
COMPENSATION
£715K
AGE
43
TENURE
2.6 yrs

Ronnie van der Merwe

TITLE
CEO & Executive Director
COMPENSATION
£5M
TENURE
0.8 yrs

Dirk Le Roux

TITLE
Chief Information Officer
COMPENSATION
£2M
AGE
58

James Arnold

TITLE
Head of Investor Relations

Magnus Oetiker

TITLE
Chief Human Resources Officer
AGE
46
TENURE
1.1 yrs

Gert Hattingh

TITLE
Chief Corporate Services Officer
COMPENSATION
£4M
AGE
53
TENURE
3.2 yrs

Biren Valodia

TITLE
Chief Marketing Officer of Medi-Clinic Southern Africa

Clara Findlay

TITLE
Chief Legal Officer of Mediclinic Southern Africa

Wimpie Aucamp

TITLE
Chief Operating Officer of Medi-Clinic for Southern Africa

Greg Wyk

TITLE
Chief Human Resources Officer of Mediclinic Southern Africa
Board of Directors Tenure

Average tenure and age of the Mediclinic International board of directors in years:

3.1
Average Tenure
62
Average Age
  • The tenure for the Mediclinic International board of directors is about average.
Board of Directors

Edwin de la Harpe Hertzog

TITLE
Non-Executive Chairman
COMPENSATION
£258K
AGE
68
TENURE
3.1 yrs

Petrus Myburgh

TITLE
Group CFO & Executive Director
COMPENSATION
£715K
AGE
43
TENURE
2.6 yrs

Ronnie van der Merwe

TITLE
CEO & Executive Director
COMPENSATION
£5M
TENURE
0.8 yrs

Desmond Smith

TITLE
Senior Independent Director
COMPENSATION
£106K
AGE
71
TENURE
2.1 yrs

J. Grieve

TITLE
Independent Non-Executive Director
COMPENSATION
£78K
AGE
66
TENURE
3.1 yrs

Trevor Petersen

TITLE
Independent Non-Executive Director
COMPENSATION
£91K
AGE
62
TENURE
3.1 yrs

Danie Meintjes

TITLE
Non-Executive Director
COMPENSATION
£1M
AGE
62
TENURE
3.1 yrs

Jannie Durand

TITLE
Non-Executive Director
COMPENSATION
£68K
AGE
51
TENURE
3.1 yrs

Seamus Keating

TITLE
Independent Non-Executive Director
COMPENSATION
£87K
AGE
54
TENURE
5.8 yrs

Felicity A. Harvey

TITLE
Independent Non-Executive Director
COMPENSATION
£33K
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
10. Aug 18 Buy Petrus Myburgh Individual 08. Aug 18 08. Aug 18 20,000 £5.03 £100,559
30. May 18 Sell Daniel Meintjes Individual 24. May 18 25. May 18 -49,423 £6.64 £-321,507
X
Management checks
We assess Mediclinic International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mediclinic International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MDC News

Simply Wall St News

Mediclinic International plc (LON:MDC): The Return Story

and looking to gauge the potential return on investment in Mediclinic International plc (LON:MDC). … This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … Therefore, looking at how efficiently Mediclinic International is able to use capital to create earnings will help us understand your potential return.

Simply Wall St -

Mediclinic International plc (LON:MDC): A Look At Return On Capital

and looking to gauge the potential return on investment in Mediclinic International plc (LON:MDC). … Your equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … To understand Mediclinic International’s capital returns we will look at a useful metric called return on capital employed.

Simply Wall St -

Why Mediclinic International plc's (LON:MDC) Investor Composition Impacts Your Returns

I am going to take a deep dive into Mediclinic International plc’s (LON:MDC) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Therefore, it is beneficial for us to examine MDC's ownership structure in more detail.

Simply Wall St -

A Look At The Intrinsic Value Of Mediclinic International plc (LON:MDC)

In this article I am going to calculate the intrinsic value of Mediclinic International plc (LON:MDC). … by taking the foreast future cash flows of the company and discounting them back to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Want To Invest In Mediclinic International plc (LON:MDC)? Here's How It Performed Lately

After reading Mediclinic International plc's (LSE:MDC) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … See our latest analysis for Mediclinic International Commentary On MDC's Past Performance For the most up-to-date info, I use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For Mediclinic International, its latest earnings (trailing twelve month) is UK£69.00M, which, relative to last year’s level, has plunged by a substantial -63.87%.

Simply Wall St -

Who Are The Major Shareholders In Mediclinic International plc (LON:MDC)?

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … An ownership of this size indicates a strong financial backing and has the potential to influence MDC's business strategy. … Thus, investors should dig deeper into MDC's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

What does Mediclinic International plc's (LON:MDC) Balance Sheet Tell Us About Its Future?

With this rise in debt, the current cash and short-term investment levels stands at UK£377.00M for investing into the business. … On top of this, MDC has produced UK£394.00M in operating cash flow over the same time period, leading to an operating cash to total debt ratio of 19.32%, signalling that MDC’s operating cash is not sufficient to cover its debt. … Next Steps: MDC’s debt and cash flow levels indicate room for improvement.

Simply Wall St -

Does Mediclinic International plc's (LON:MDC) PE Ratio Warrant A Sell?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for MDC Price per share = £5.7 Earnings per share = £0.094 ∴ Price-Earnings Ratio = £5.7 ÷ £0.094 = 60.9x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … For example, if you accidentally compared lower growth firms with MDC, then MDC’s P/E would naturally be higher since investors would reward MDC’s higher growth with a higher price.

Simply Wall St -

With A -63.87% Earnings Drop, Is Mediclinic International plc's (LON:MDC) Performance A Concern?

For Mediclinic International, its most recent trailing-twelve-month earnings is UK£69.00M, which compared to the prior year's figure, has declined by a significant -63.87%. … This shows that whatever recent headwind the industry is facing, it’s hitting Mediclinic International harder than its peers.What does this mean? … However, if the entire industry is struggling to grow over time, it may be a indicator of a structural change, which makes Mediclinic International and its peers a riskier investment.

Simply Wall St -

Calculating The Fair Value Of Mediclinic International plc (LON:MDC)

5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (£, Millions) £53.00 £308.35 £338.00 £271.40 £304.58 Source Analyst x1 Analyst x2 Analyst x2 Analyst x1 Extrapolated @ (12.23%) Present Value Discounted @ 8.3% £48.94 £262.91 £266.11 £197.30 £204.46 Present Value of 5-year Cash Flow (PVCF)= £980 We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = £305 × (1 + 1.5%) ÷ (8.3% – 1.5%) = £4,541 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = £4,541 / ( 1 + 8.3%)5 = £3,048 The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is £4,028. … LSE:MDC Intrinsic Value Jan 22nd 18 Important assumptions I'd like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows.

Simply Wall St -

MDC Company Info

Description

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 private acute care hospitals and 4 clinics with approximately 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,131 inpatient beds; and 6 acute care private hospitals and 22 clinics with approximately 748 inpatient beds in the United Arab Emirates. The company also provides treasury, hospital equipment, debt collection and related, emergency medical, management, food and catering, procurement, and healthcare management services; manages healthcare staff; and owns and manages properties. In addition, it engages in intellectual property holding and medical store/procurement businesses. Mediclinic International plc was founded in 1983 and is based in Stellenbosch, South Africa.

Details
Name: Mediclinic International plc
MDC
Exchange: LSE
Founded: 1983
£2,345,484,459
737,110,138
Website: http://www.mediclinic.com
Address: Mediclinic International plc
25 Du Toit Street,
Stellenbosch,
Western Cape, 7600,
South Africa
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE MDC Ordinary Shares London Stock Exchange GB GBP 16. Feb 2016
DB MO4 Ordinary Shares Deutsche Boerse AG DE EUR 16. Feb 2016
NMSE MEP Ordinary Shares Namibian Stock Exchange NA ZAR 16. Feb 2016
JSE MEI Ordinary Shares The Johannesburg Securities Exchange ZA ZAR 16. Feb 2016
BATS-CHIXE MDCL Ordinary Shares BATS 'Chi-X Europe' GB GBP 16. Feb 2016
Number of employees
Current staff
Staff numbers
33,629
Mediclinic International employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 21:47
End of day share price update: 2019/03/20 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2018/11/15
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.